Beta Drugs (NSE:BETA) Total Debt per Share: ₹0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BETA Beta Drugs Ltd NSE:BETA
91 GF Score
Price ₹2,307.00
GF Value ₹2,701.88
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Beta Drugs Total Debt per Share?

Beta Drugs NSE:BETA -0.89% 91 Total Debt per Share is ₹0.00 as of Jun. 2026. GuruFocus rates NSE:BETA with a GF Score™ of 91/100 and a GF Value™ of ₹2,701.88 (Modestly Undervalued). The stock has 6 warning signs investors should review.

₹0.00 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Beta Drugs's Total Debt Per Share for the quarter that ended in Jun. 2026 was ₹0.00.

Beta Drugs Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Beta Drugs's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs Total Debt per Share Chart

Beta Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.41 20.14 14.57 136.76 145.80

Beta Drugs Quarterly Data
Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 288.74 0.00 145.87 0.00
NSE:BETA
91GF Score
Beta Drugs Ltd NSE:BETA
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Drugs Total Debt per Share Calculation

Beta Drugs's Total Debt Per Share for the fiscal year that ended in Mar. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(1,333+145)/10
=145.79

Beta Drugs's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0+0)/11
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of ₹0.00 mean?
Beta Drugs (NSE:BETA) has a Total Debt per Share of ₹0.00 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Beta Drugs and its competitors.
Is Beta Drugs' Total Debt per Share too high?
Beta Drugs' current Total Debt per Share is ₹0.00. Overall, Beta Drugs has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Total Debt per Share compare to ZTS?
Beta Drugs' Total Debt per Share of ₹0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Drug Manufacturers company?
A good Total Debt per Share depends on the Drug Manufacturers industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Beta Drugs and its competitors. Beta Drugs's current Total Debt per Share is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,701.88, compared to a current price of ₹2,307.00 — trading 14.6% below its estimated fair value. The current Total Debt per Share is ₹0.00. Beta Drugs' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Total Debt per Share is ₹0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be undervalued. The current stock price of ₹2,307.00 is trading 14.6% below its estimated GF Value™ of ₹2,701.88. GuruFocus considers Beta Drugs to be Modestly Undervalued.

Key valuation signals for NSE:BETA:

  • Total Debt per Share: ₹0.00
  • GF Value™: ₹2,701.88 vs. price of ₹2,307.00 (14.6% below fair value)
  • GF Score™: 91/100 with 6 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
91GF Score

Get the complete analysis for NSE:BETA

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,307.00
Price
₹2,701.88
GF Value